1. Home
  2. ERII vs PHVS Comparison

ERII vs PHVS Comparison

Compare ERII & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Energy Recovery Inc.

ERII

Energy Recovery Inc.

HOLD

Current Price

$14.18

Market Cap

740.3M

Sector

Technology

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$25.82

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ERII
PHVS
Founded
1992
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
740.3M
1.7B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
ERII
PHVS
Price
$14.18
$25.82
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$16.50
$39.44
AVG Volume (30 Days)
478.9K
532.0K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
7.56
N/A
EPS
0.36
N/A
Revenue
$135,191,000.00
N/A
Revenue This Year
$5.93
N/A
Revenue Next Year
$8.97
N/A
P/E Ratio
$39.45
N/A
Revenue Growth
0.10
N/A
52 Week Low
$10.86
$11.51
52 Week High
$18.32
$29.80

Technical Indicators

Market Signals
Indicator
ERII
PHVS
Relative Strength Index (RSI) 41.68 54.34
Support Level $14.11 $23.79
Resistance Level $14.75 $25.44
Average True Range (ATR) 0.36 1.91
MACD 0.02 -0.17
Stochastic Oscillator 2.06 41.22

Price Performance

Historical Comparison
ERII
PHVS

About ERII Energy Recovery Inc.

Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: